Endo Int'l (ENDP) Tops Q2 EPS by 12c, Affirms Guidance

Endo Int'l (NASDAQ: ENDP) reported Q2 EPS of $0.86, $0.12 better than the analyst estimate of $0.74. Revenue for the quarter came in at $921 million versus the consensus estimate of $864.34 million.

Company affirms full year 2016 revenue and adjusted diluted EPS financial guidance.

Company expands management capabilities, appointing Joseph J. Ciaffoni to President, U.S. Branded Pharmaceuticals.

"During the second quarter 2016, Endo remained focused on operational execution. We have delivered results across all of our businesses that are on-track or ahead of Company expectations for the quarter and today we are affirming our full year 2016 revenue and adjusted diluted EPS financial guidance while increasing investment in Branded and Generics R&D as well as BELBUCA™ and XIAFLEX® promotion," said Rajiv De Silva, President and CEO of Endo. "We also continue to build our internal team and are pleased to announce the appointment of Joseph J. Ciaffoni to President, U.S. Branded Pharmaceuticals. We look forward to continuing to execute on our corporate objectives and delivering products that improve patients' lives while creating value for our shareholders."

For earnings history and earnings-related data on Endo Int'l (ENDP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Faeth Therapeutics names two SVPs ahead of clinical milestones
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c